Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Oral bexarotene is safe and effective in a phase II-III clinical trial in refractory or persistent early stage CTCL. Duvic, M., Martin, A., Kim, Y., Olsen, E., Wood, G., Yocum, R. AMER SOC HEMATOLOGY. 1999: 659A
View details for Web of Science ID 000083790302976